Updated:
Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. is a publicly traded pharmaceutical company targeting central nervous system disorders and orphan drug indications.
Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. was incorporated as a Delaware corporation, though its founding year is not publicly standardized. The company is publicly traded, which distinguishes it from the typical private family office structure. Its focus is on central nervous system disorders and pain management, with a stated intent to use an orphan drug strategy for accelerated regulatory pathways. The company's investment posture centers on in-house drug development and strategic acquisitions. It has not disclosed specific portfolio companies or named co-investors. Public filings indicate operations in Canada and the United States, but no confirmed deployment figures or AUM. Raphael Pharmaceutical maintains a small team consistent with its developmental-stage status. No separate offices outside the Delaware headquarters are publicly identified. No adjacent vehicles like foundations or operating companies have been disclosed. The structural differentiator for Raphael Pharmaceutical is its status as a special purpose acquisition company, a vehicle designed to acquire or merge with an existing business. This structure imposes a finite timeframe for executing a transaction, unlike traditional pharmaceutical firms or family offices with indefinite mandates. (per public filings, 2024)
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Raphael Pharmaceutical?
The firm is led by a management team that reports to a board of directors, as is standard for a publicly traded company. Specific named principals beyond the CEO are not widely identified in public filings.
How does Raphael Pharmaceutical source proprietary deal flow?
The firm sources proprietary opportunities through its status as a special purpose acquisition company, which involves identifying a target business for merger or acquisition. It does not operate a traditional fund or direct investment program.
Is Raphael Pharmaceutical structured as a family office or a venture firm?
Raphael Pharmaceutical is a publicly traded corporation, not a family office or venture capital firm. Its structure is that of a special purpose acquisition company with a mandate to acquire or merge with a life sciences business.
Does Raphael Pharmaceutical participate in fund commitments or only direct deals?
The firm engages in direct deals via its acquisition mandate. It does not make fund commitments or co-investments as a limited partner.
What investment stages does Raphael Pharmaceutical typically target?
The firm targets developmental-stage pharmaceutical assets, particularly those with orphan drug potential for central nervous system and pain indications. It does not invest in early-stage venture or public equities outside its own operations.
Which sectors does Raphael Pharmaceutical explicitly avoid?
The firm focuses exclusively on pharmaceuticals and biotechnology, avoiding non-life sciences sectors entirely.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: